Bone-Marrow Purging with Monoclonal Antibodies and Human Complement in ALL and AML
High-dose treatment followed by infusion of histocompatible allogeneic bone marrow has been shown to be curative in many patients with acute leukemia. Inherent in this treatment modality are a number of problems, however. Most prominent among them: graft versus host disease or, when using T cell-depleted marrow, graft failure. In addition, age restriction, conventionally applied to minimize morbidity and mortality, reduces the application of allogeneic bone marrowtransplantation to, on the average, about one third of those with the disease, and of these only about one in three will have a suitable donor.
KeywordsLeukemia Oncol Tocol Midine Progeni
Unable to display preview. Download preview PDF.
- 7.Knapp W, Majdic O, Stockinger H, Bettelheim P, Liszka K, Köller U, Peschel C (1984) Med Oncol Tumor Pharmacother 4:257–262Google Scholar